Royal Philips announced FDA 510(k) clearance for Elevate Plus, an AI-powered software suite for its EPIQ Elite and Affiniti ultrasound systems. The technology features automated measurement capabilities, workflow automation, and AI decision support for lesion classification, designed to reduce scanning time by up to 30% while maintaining clinical accuracy and helping healthcare providers manage growing demand.

Royal Philips announced on June 2, 2026, that it will issue 19,964,655 new common shares as part of its 2025 dividend distribution, with an exchange ratio of 1 new share for every 26.9341 existing shares. The dividend was calculated to be approximately EUR 0.85 per share based on a three-day volume-weighted average price of EUR 22.8640. Shareholders chose a 43.8% cash election option, with the remaining shareholders receiving shares. The total issued share capital will reach EUR 196,576,957.40 representing 982,884,787 common shares upon distribution.

The global nebulizer market is projected to grow from US$1.5 billion in 2025 to US$2.2 billion by 2032 at a CAGR of 5.9%. Growth is driven by rising respiratory disease prevalence, aging populations, technological advancements in mesh and smart nebulizers, and increasing adoption of home healthcare solutions. Key market segments include jet nebulizers, ultrasonic nebulizers, and mesh nebulizers across hospitals, clinics, and home settings.

Royal Philips is presenting advanced cardiac intervention technologies at EuroPCR 2026 in Paris, including SmartIQ (reducing radiation dose by over 50%), IntraSight Plus, DeviceGuide, and VeriSight Pro 3D ICE. These innovations aim to help interventional cardiologists manage complex procedures while reducing radiation exposure for patients and staff through integrated imaging, physiology, and AI-enabled guidance workflows.

The global computer vision in healthcare market is projected to grow from $4.37 billion in 2026 to $33.4 billion by 2036, at a CAGR of 22.6%. Growth is driven by AI-integrated diagnostic systems, radiologist shortages, and precision medicine adoption. Software and medical imaging segments lead the market, while Asia-Pacific is expected to see the fastest regional growth.

The global healthcare analytics market is projected to grow from USD 56 billion in 2025 to USD 390 billion by 2034, with a CAGR of ~24%. Growth is driven by widespread EHR adoption, rising chronic disease prevalence, shift toward value-based care, AI/ML integration, and government digital health initiatives. North America leads with 44.36% market share, while Asia-Pacific emerges as a major growth engine.

Koninklijke Philips reported strong Q1 2026 results with 6% order intake growth and 4% comparable sales increase, beating earnings expectations at 27 cents per share versus 23 cents consensus. However, sales of $4.57 billion slightly missed the $4.60 billion consensus. The company maintained its 2026 outlook for 3%-4.5% comparable sales growth and 12.5%-13.0% adjusted EBITA margin. Stock was up 2.72% at $27.17 despite technical indicators showing fading momentum.

The global sleep apnea devices market is expected to grow at a CAGR of 7.05% from 2025 to 2034, driven by rising prevalence of sleep apnea affecting approximately 1 billion people worldwide, increased obesity rates, and technological innovations in CPAP, BiPAP, and oral appliances. Growth is further supported by expanding homecare and telemedicine adoption. However, challenges include high device costs, limited access in developing regions, and poor patient compliance with therapy.

Royal Philips announced the launch of Bridge Plus Occlusion Balloon, a next-generation device designed to rapidly control bleeding during rare superior vena cava (SVC) tears in transvenous lead extraction procedures. The device can deploy in under two minutes, stop up to 90% blood loss, and maintain hemostasis for 30 minutes. Clinical evidence shows survival rates improved from 56.9% to 88.2% when an occlusion balloon was staged in advance. The product is now commercially available in the United States with international availability expected later in 2026.

The global respiratory care devices market is projected to grow from USD 24.3 billion in 2025 to USD 47.5 billion by 2034, at a CAGR of ~8%. Growth is driven by rising prevalence of chronic respiratory diseases (COPD, asthma, sleep apnea), increasing demand for home healthcare solutions, technological advancements, and post-COVID-19 awareness. North America leads with 41% market share, followed by Europe and Asia-Pacific.

Royal Philips announced FDA 510(k) clearance for its Rembra platform, including Rembra CT, Rembra RT, and Areta RT systems. The platform is designed to improve speed, efficiency, and access to high-quality imaging for diagnostic radiology and radiation therapy planning, supporting up to 270 exams per day with an 85 cm bore.

The global ambulatory surgical equipment market is valued at USD 7.39 billion in 2026 and is expected to reach USD 14.58 billion by 2035, growing at a 7.85% CAGR. North America dominates with 34% market share, while Asia Pacific is the fastest-growing region. Endoscopy and laparoscopy systems lead by product type at 18% share, with compact intraoperative imaging expected to grow fastest. Independent ambulatory surgical centers account for 42% of the market.